Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03781752 · ClinicalTrials.gov registry record · Phase 4
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
A Phase 4 study of Attention Deficit Hyperactivity Disorder and ADHD, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
- 4
- Study locations
NCT03781752: Recruiting Phase 4 study of Attention Deficit Hyperactivity Disorder and ADHD, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03781752 is a Phase 4 study of Attention Deficit Hyperactivity Disorder and ADHD that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 500 participants, above the 212-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (136% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03781752, a Phase 4 study of Attention Deficit Hyperactivity Disorder and ADHD, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Conditions Studied
Interventions
- DRUG Methylphenidate
Study Locations (4)
Florida
- University of Florida - Gainesville
New York
- Icahn School of Medicine at Mount Sinai - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2018-03-04 |
| Est. Completion | 2025-08 |
| Phase | Phase 4 |
What NCT03781752 shows while recruiting
NCT03781752 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 212-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (136% higher).
The record links to 2 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Methylphenidate is the first listed.
NCT03781752 reports a single indexed study location in Florida, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT03781752 about?
NCT03781752 is a clinical study titled "Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD". The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
What is the current status of trial NCT03781752?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2018-03-04. Estimated completion is 2025-08.
What conditions does trial NCT03781752 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, ADHD.
What interventions are being tested in trial NCT03781752?
The interventions under investigation include: Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT03781752?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03781752 being conducted?
This trial has 4 study locations across Florida, New York, Ohio, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03781752's enrollment target sits among peer trials
500 9th of 102 higher than 93 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
R61/33 - VR Study Phase 4
RECRUITING · Phase 4
-
A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
RECRUITING · Phase 4
-
Stimulant Effects on Disruptive Behavior
RECRUITING · Phase 4
-
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
RECRUITING · Phase 4
-
An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI